Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast, Q1'26

By Inderes5/12/2026, 8:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 08:47

Welcome, everyone, to the webcast for Ascelia Pharma AB Q1 report for 2026. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma AB and recent key events, and then we'll head into the portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions. Ascelia Pharma AB. We identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. Our company is based in Malmo, Sweden, and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug that is now under FDA review, with a PDUFA date of July 3, 2026. We will spend the majority of this call talking about Orviglance. ONCORAL is a patented tablet formulation of irinotecan, with encouraging results in Phase 1 and potential to treat a range of solid tumors. Regarding the progress of the first quarter this year, we participated in the European Society for Gastrointestinal and Abdominal Radiology (ESGAR) Conference. There will be an oral presentation about Orviglance by Professor Dominique Geisel from the Charité Hospital in Berlin. Dr. Geisel was an investigator in our Phase 3 study, and Charité is one of the largest hospitals in Europe. During the first quarter, our previously communicated changes in the management team took place as Anton Hansson started as our Chief Financial Officer, and Julie Waras Brogren left Ascelia Pharma; after the close of the quarter in April, we made a directed share issue and raised 20 million Swedish kronor before cost, which extends our cash runway into 2027. We're focused on our two key strategic goals: Orviglance approval and Orviglance partnering. I'm happy to say that we're on track with both of them for the approval. The milestones are the submission of the NDA on September 3rd last year, and in mid-November last year, the FDA set the due date of July 3rd, 2026. This is the date. The due date is the date where the FDA expects to make a decision on the approval of the Orviglance New Drug Application. Our NDA activities, including the interactions with the FDA, are progressing well, and we continue to be on track for the approval. The second objective is to progress Orviglance for commercialization. This is a two-pronged approach. One is to continue to advance launch readiness by ensuring manufacturing and supply chain are ready for launch, as well as working with medical experts, key opinion leaders, payers, and other key stakeholders to ensure the product will have a successful launch whenever that happens in partnership; the other track is to enter into a deal with a partner who will lead and drive the commercialization. I'm proud of the team and the progress we are making on these important milestones, and I'm optimistic for a very strong 2026 for Ascelia Pharma. We will start the portfolio section of our presentation with Orviglance. We are very excited about Orviglance, and here's why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million addressable global market opportunity for Orviglance. Orviglance is a first-in-class product to target this and has Orphan Drug Designation from the FDA. We have commercial scale manufacturing in place, and we have strong data from nine clinical studies, including compelling Phase 3 data. As mentioned, the Orviglance new drug application has been submitted to the FDA, and the due date is coming up in less than two months. Orviglance is an attractive asset that can help patients, and we will work with a partner to drive the commercialization. Let's talk about how Orviglance can help patients. Cancer of the liver is a significant challenge in cancer care. Many different cancer types metastasize to the liver, meaning they start in one organ and spread to the liver. This accounts for roughly 90% of cancer in the liver in the US and Europe. The remaining 10% of cancer of the liver is when the cancer originates in the liver. The liver is often the first organ where the cancer spreads to, and also often the cause of death. That is why cancer in the liver is a major issue in cancer care, and therefore it is important to perform high-quality medical imaging to determine if the cancer has spread to the liver and how the cancer in the liver is responding to therapy or for surgical planning. The best way to do this is with Liver MRI, and to use a Gadolinium-based contrast agent. For most patients, this works well. However, for patients with severe renal disease, they are at risk of a potentially fatal gadolinium-induced side effect known as nephrogenic systemic fibrosis. Regulatory agencies have requested a Black Box Warning on gadolinium products because of this risk. It is exactly these patients that we aim to help with. Orviglance provides high quality imaging, and because it is based on Manganese, there are none of the gadolinium-associated risks. This unmet medical need translates into a global addressable market opportunity of $800 million on an annual basis. The US market is almost half of this, and therefore we have prioritized the US market. Ascelia will work with partners to drive the commercialization of Orviglance. Let's talk a bit more about the key metrics for the US market based on real-world data. There are about 100,000 relevant procedures in the Orviglance target population every year in the US because of their disease and comorbidities. These patients are mostly treated at the major medical centers, and 75% of these imaging procedures are made at the 400 largest Medicare accounts. Based on market research, pricing benchmarks for high-value diagnostic drugs can range from $3,000 to $4,500 per dose. Orviglance is addressing a well-recognized medical need. As mentioned previously, Orviglance is targeting patients with severe renal disease because of the gadolinium associated risks. The medical community is well aware of this, and our market research demonstrates that more than 90% of healthcare professionals are concerned about gadolinium-associated risk, and a number of them have also experienced nephrogenic systemic fibrosis in patients. Orviglance is targeting patients with severe renal impairment, which is the highest-risk population defined by the black box warning. With every gadolinium injection, there is also a deposition of gadolinium in tissue in the body, including in the brain. Every gadolinium injection, there is also a deposition of gadolinium in tissues throughout the body, including in the brain. The consequences of this continue to be evaluated in the scientific community, including long-term effects of the deposition. Another issue is the gadolinium accumulation in our water supply. After the gadolinium contrast injection, the gadolinium is excreted in the urine, which goes into our sewer system, and filtration systems are unable to remove the gadolinium. And as a consequence, gadolinium content in drinking water has increased over the last decades. These are important drivers for the future of MRI. Ascelia Pharma is leading the charge, with Orviglance being based on manganese and under FDA review. If and when approved, it will be the only manganese product on the market. The gadolinium manufacturers recognized the gadolinium challenges. GE HealthCare is developing an injectable manganese agent. They have completed a Phase 1 study and have recently started a Phase 2/3 study. We consider this a positive development with increased focus on manganese agents, and based on what we know, these two products are complementary to each other. The other gadolinium manufacturers have developed gadolinium products with lower doses of gadolinium to reduce the impact. These underlying developments support the need for products such as Orviglance, and we believe the timing for bringing Orviglance to the market is good. We have a clearly stated strategic goal of entering into a partnership with a company that will lead the commercialization of Orviglance. Orviglance represents an attractive commercial opportunity, and we are making good progress in our partnering dialogues. Now we'll transition to the scientific and regulatory section. And Andreas, please go ahead.

Andreas Norlin
08:48 - 15:00

Thank you Magnus. Before I talk about the NDA process, just a few words about the development program of Orviglance. We have an extensive clinical development program, including a total of 286 patients and healthy volunteers across nine clinical studies. Together, these studies have shown a strong, consistent positive benefit-risk profile supporting the intended use in patients in need of a liver MRI and with severe renal impairment. The phase three study, SPARKLE demonstrated that visualization of focal liver lesions measured by the co-primary efficacy variables border delineation and lesion contrast clearly improved with Orviglance compared to unenhanced imaging with a high degree of statistical significance. We could also see that more lesions, especially smaller ones, could be detected in the liver with Orviglance than without. So to summarize, we've built a strong and compelling data package supporting the use of Orviglance in a patient population with a clearly defined and significant unmet medical need. Based on that, we successfully submitted our NDA in September last year, and since then the review has progressed as expected, with a target date for FDA's final decision on July 3rd. Because Orviglance has Orphan Drug Designation for its intended population, we expect to benefit from seven years of regulatory exclusivity following approval. In addition, we filed new patent applications that could extend protection well into the 2040s, further enhancing the long-term commercial opportunity for the product. Overall, we're really pleased with where we are and are very much looking forward to the final stretch leading up to FDA's expected final decision on July 3rd. While our primary focus right now is on securing a successful approval and partnering for Orviglance, we also have Oncoral in our portfolio. That program remains an important asset, and we are looking forward to re-initiation when the timing is right. I'd like to say a few words about that opportunity as well. ONCORAL is a tablet formulation of irinotecan, a well-established intravenous chemotherapeutic agent. A tablet formulation enables a frequent daily, low dose dosing regimen that could offer potential advantages on both efficacy and safety compared to the infrequent high dose intravenous administration that is used today. The opportunity of improving efficacy and safety by administration of daily low doses, also called metronomic dosing, has been demonstrated for irinotecan and other chemotherapeutic agents. In our Phase 1 studies with ONCORAL, we've seen encouraging results that suggest that oral daily administration of irinotecan could offer meaningful benefits to patients. Importantly, the ONCORAL studies have demonstrated an acceptable safety profile and that the uptake of the drug after oral administration is well suited for a metronomic dosing approach. This supports the continued development of ONCORAL as a daily oral formulation of irinotecan. Our plan is to bring ONCORAL into clinical Phase 2 in gastric cancer. Animal data has demonstrated a synergistic effect of irinotecan when combined with Lonsurf, another oral cancer treatment already approved for gastric cancer, which makes this all oral combination very interesting. The plan is to demonstrate clinical proof of concept for the combination of ONCORAL and Lonsurf in gastric cancer. And we start there, and this is today a $3 billion market. Irinotecan is a well-established chemotherapy with recognized anti-tumor effects in many types of solid tumors. Therefore, we see opportunities for developing ONCORAL in other indications where daily dosing could positively impact efficacy and safety outcomes for patients. And we are assessing these opportunities as part of our ongoing strategic planning for ONCORAL. So let's move on to an update of the financials. Anton. Thank you. Andreas. So I will now move on to an update of our financials. And in Q1, our operating results amounted to a loss of 17 million Kroners. And the costs are lower in the quarter compared to Q1 2025 due to the completion of the NDA. At the end of March, we had 34 million in liquid assets. And as Magnus mentioned earlier, after the quarter ended, we successfully completed a directed share issue, raising 20 million SEK before costs in April, and we have now extended our cash runway into 2027. And to summarize, we have significant value creation opportunities ahead. With Orviglance, we are bringing a first-in-class diagnostic drug to market, addressing an $800 million market for patients with high unmet need. And our two key objectives remain timely approval of Orviglance with an optimal label. And here in early September, we submitted the NDA, and the FDA accepted the Orviglance NDA for review in mid-November. And based on a standard ten-month review process, we can expect an approval early July 2026. Our second objective is to progress Orviglance for commercialization for patients in need by entering into a partnering agreement for the launch. These efforts continue to advance. So overall, we continue to progress in Q1 and are well positioned to deliver on our key milestones, and we look forward to continuing our journey with these opportunities for growing Ascelia Pharma AB.

Magnus Corfitzen
15:02 - 15:08

That concludes our quarterly presentation. And now we'd like to open up for questions.

Operator
15:09 - 15:28

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Maria Carlsen Osipova from DAB Carnegie. Please go ahead.

Maria Carlsen Osipova
15:30 - 16:07

Hello. Good morning Ascelia team. I have two short questions. Thank you for the presentation. And of course, obviously all eyes on PDUFA date. And then the report. You state that you're working actively to answer all of the FDA supplementary questions. And in previous calls and reports, you have described this as. And it is a standard back and forth process with the agency. So basically, my question is, has the nature or volume of the questions changed somehow as you're now entering the final stretch? And if you could maybe characterize the types of areas that the agency is now focused on.

Andreas Norlin
16:10 - 16:47

Thank you for that question. I think the simple answer is that we have received questions across the board, and that is, of course, what you expect. FDA is reviewing all sections: efficacy, safety, CMC, nonclinical. And we have received questions. All over. At the end of the review period, you enter the negotiation or discussion about the label. And that is what we expect also here at the end. But everything has been flowing nicely so far.

Maria Carlsen Osipova
16:49 - 17:12

That's good to hear. And another short one. If the FDA approves this on July 3rd, what happens on July 4th or... I think it's Friday. So what happens on July 6th then? Can you walk us through the process? What do the coming 90 days or so look like? What's already in place and what still depends on the potential partner? Maybe.

Magnus Corfitzen
17:14 - 18:08

So you could say, at least as I understand it, we get an approval letter, which will probably hang up. So, have a sort of a copy on the wall to celebrate. I think that's obviously a major transformative milestone. There are some administrative things for setting everything in place, but the next step is getting ready for launch and all the activities that go into that. And as we've said, we want to work with a partner who will drive the commercialization. We have done a lot of work to prepare that. So we have some roadmaps, blueprints, and a lot of market insights. That is going to help the partner get moving fast. So, I think we will work with the partner to make sure everything is lined up for the launch.

Maria Carlsen Osipova
18:13 - 18:16

All right. Thank you. I don't have any more questions. Thank you very much.

Magnus Corfitzen
18:16 - 18:17

Yeah. Thank you Maria.

Operator
18:19 - 18:31

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. The next question comes from Frederick Thaw from Redeye. Please go ahead.

Frederick Thaw
18:33 - 19:10

Hello. Thank you. Thank you. I have a follow-up question for Maria regarding the approval in July. Are there any one-time costs associated with the approval process, or any recurring costs related to the approval that will cease after it? So basically, will the cost development be in a specific way after the approval or will it be quite? Quite stable cost development after the approval. Potential approval?

Magnus Corfitzen
19:13 - 19:46

Yeah. Well, thank you for the question. We're not providing specific cost guidance. I think obviously, responding to questions and requests involves both internal and external experts. And so obviously, it's not for free to be in this process. On the other hand, we also envision other activities after the approval. So I think at this point, we're not expecting major significant changes in our cost structure.

Frederick Thaw
19:49 - 19:52

Got it. That's my question. Thank you very much.

Operator
19:53 - 20:01

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
20:04 - 22:07

There's a question here on whether it's a partnering strategy to complete the negotiations after positive feedback. So I think the overall strategy that we have is to line up for partnering. We have completed the clinical development, finalized the NDA, and are now running the FDA review process. And as we said, we are on track for approval, which I think I'm very proud of the team that can achieve these very challenging milestones. And I think that's a great achievement so far. I think that those achievements also generate value and create a good dynamic in the partnering conversations. The partners are focused on preparing what their commercial team would look like and what is required for the commercial opportunity. And I would say significantly less on the scientific part, because the FDA is basically doing the diligence on that part. So I think that is creating some good dynamics, whether we sign an agreement before the FDA decision or after. It's hard to tell. Obviously from a partner perspective, you have lower risk after the approval. But on the other hand, you could structure the deal in a way where you take out some of the risk on the FDA decision, but I think it could be either or; time will tell where we end up. There are no more questions. So thank you all for joining our Q1 call. And we are, as I mentioned, on track for FDA approval and on our partnering process. So, a very exciting 2026 for Ascelia Pharma AB. And we look forward to updating you on our progress as the year goes on.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…